Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

By BiotechDaily International staff writers
Posted on 26 Aug 2014
Print article
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).
An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions.

To promote development of low molecular weight ion transporter drugs, investigators at The University of Texas, Austin (USA) sought to show that there was a direct correlation between a change in cellular chloride anion concentration and cytotoxicity for synthetic ion carriers.

To accomplish this goal, the investigators and their colleagues from five other research institutes created two synthetic ion transporters—pyridine diamide-strapped calix[4]pyrroles—that bind to chloride ions.

Results published in the August 11, 2014, online edition of the journal Nature Chemistry revealed that these compounds induced coupled chloride anion and sodium cation transport in both liposomal models and cells, and promoted cell death by increasing intracellular chloride and sodium ion concentrations. Removing either ion from the extracellular media or blocking natural sodium channels prevented this effect.

“We have demonstrated that this mechanism is viable, that this idea that has been around for over two decades is scientifically valid, and that is exciting,” said contributing author Dr. Jonathan L. Sessler, professor of chemistry at the University of Texas, Austin. “We were able to show sodium is really going in, chloride is really going in. There is now, I think, very little ambiguity as to the validity of this two-decades-old hypothesis. We have shown that this mechanism of chloride influx into the cell by a synthetic transporter does indeed trigger apoptosis. This is exciting because it points the way towards a new approach to anticancer drug development.”

The synthetic molecules described in the current study induce programmed cell death in both cancerous and healthy cells. To be of any value in treating cancer, a version of a chloride anion transporter will have to be developed that acts only on cancer cells.

Related Links:

The University of Texas, Austin



Print article

Channels

Genomics/Proteomics

view channel
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).

Statins May Help Block Transmission of Lyme Disease

A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease. Lyme disease... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.